| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10485145 | Value in Health | 2012 | 10 Pages |
Abstract
The combination of 5FU and irinotecan (whether used first or second line) appears to be more cost-effective than the single agent sequential therapies used in the FOCUS trial, or 5FU plus oxaliplatin.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Andrea MSc, PhD, Christian PhD, Yolanda MSc, Matt T. MB, BS, Angela PhD, Richard PhD, Mahesh PhD, Mark J. MSc, PhD,